These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32779449)

  • 1. Induced Pluripotent Stem Cell Meets Severe Combined Immunodeficiency.
    Kouchaki R; Abd-Nikfarjam B; Maali AH; Abroun S; Foroughi F; Ghaffari S; Azad M
    Cell J; 2020 Jul; 22(suppl 1):1-10. PubMed ID: 32779449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review.
    Kalman L; Lindegren ML; Kobrynski L; Vogt R; Hannon H; Howard JT; Buckley R
    Genet Med; 2004; 6(1):16-26. PubMed ID: 14726805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Health Outcome and Quality of Life Post-HSCT for IL7Rα-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: a Single Center Report.
    Abd Hamid IJ; Slatter MA; McKendrick F; Pearce MS; Gennery AR
    J Clin Immunol; 2018 Aug; 38(6):727-732. PubMed ID: 30105620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests.
    Themeli M; Chhatta A; Boersma H; Prins HJ; Cordes M; de Wilt E; Farahani AS; Vandekerckhove B; van der Burg M; Hoeben RC; Staal FJT; Mikkers HMM
    Stem Cell Reports; 2020 Feb; 14(2):300-311. PubMed ID: 31956083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
    Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
    Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel RAG1 mutation and the occurrence of mycobacterial and Chromobacterium violaceum infections in a case of leaky SCID.
    Khan TA; Iqbal A; Rahman H; Cabral-Marques O; Ishfaq M; Muhammad N
    Microb Pathog; 2017 Aug; 109():114-119. PubMed ID: 28552805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model.
    Alzubi J; Pallant C; Mussolino C; Howe SJ; Thrasher AJ; Cathomen T
    Sci Rep; 2017 Sep; 7(1):12475. PubMed ID: 28963568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress and potential applications of induced pluripotent stem cell technology].
    Wu CL; Zhang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):883-8. PubMed ID: 25130797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future.
    Maali A; Atashi A; Ghaffari S; Kouchaki R; Abdolmaleki F; Azad M
    Curr Stem Cell Res Ther; 2018; 13(8):665-675. PubMed ID: 30068283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.
    El Khatib MM; Ohmine S; Jacobus EJ; Tonne JM; Morsy SG; Holditch SJ; Schreiber CA; Uetsuka K; Fusaki N; Wigle DA; Terzic A; Kudva YC; Ikeda Y
    Stem Cells Transl Med; 2016 May; 5(5):694-702. PubMed ID: 26987352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells.
    Wiekmeijer AS; Pike-Overzet K; IJspeert H; Brugman MH; Wolvers-Tettero IL; Lankester AC; Bredius RG; van Dongen JJ; Fibbe WE; Langerak AW; van der Burg M; Staal FJ
    J Allergy Clin Immunol; 2016 Feb; 137(2):517-526.e3. PubMed ID: 26441229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications.
    Bragança J; Lopes JA; Mendes-Silva L; Almeida Santos JM
    World J Stem Cells; 2019 Jul; 11(7):421-430. PubMed ID: 31396369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem cells and severe combined immunodeficiency: merely disease modeling or potentially a novel cure?
    Mikkers H; Pike-Overzet K; Staal FJ
    Pediatr Res; 2012 Apr; 71(4 Pt 2):427-32. PubMed ID: 22430378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation.
    Samata B; Kikuchi T; Miyawaki Y; Morizane A; Mashimo T; Nakagawa M; Okita K; Takahashi J
    J Neurosci Methods; 2015 Mar; 243():68-77. PubMed ID: 25662444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation of Human Induced Pluripotent Stem Cell (iPSC) Lines and Mechanism of Pluripotency: Historical Perspective and Recent Advances.
    Chhabra A
    Stem Cell Rev Rep; 2017 Dec; 13(6):757-773. PubMed ID: 28918520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.
    Wang X; Rivière I
    Mol Ther Methods Clin Dev; 2017 Jun; 5():96-105. PubMed ID: 28480310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
    Omole AE; Fakoya AOJ
    PeerJ; 2018; 6():e4370. PubMed ID: 29770269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.